PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2020210
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2020210
Amyotrophic Lateral Sclerosis Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of amyotrophic lateral sclerosis (ALS) therapeutics Market
The global amyotrophic lateral sclerosis (ALS) therapeutics market was valued at USD 0.89 billion in 2025 and is projected to grow to USD 1.03 billion in 2026, ultimately reaching USD 2.19 billion by 2034, registering a CAGR of 9.93% during the forecast period of 2026-2034. North America led the market in 2025 with a share of 54.37%, attributed to the commercialization of approved drugs and heightened awareness of ALS in the region.
ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that weakens muscles and impairs physical function. Although no cure exists, treatments such as tofersen, edaravone, and riluzole help manage symptoms and slow disease progression. The rising prevalence of ALS and increasing awareness driven by organizations like ALS Association, I AM ALS, ACELA, ALS Netherlands, and others have boosted market demand for therapeutics.
During the COVID-19 pandemic, the ALS therapeutics market experienced a decline due to reduced hospital visits for diagnosis and treatment, along with supply chain disruptions. However, market recovery occurred in 2021-2022 as the disease burden increased and more patients sought effective care.
Market Trends
One of the key trends in the market is the development of novel drugs for ALS treatment. Companies are actively engaging in clinical trials to bring innovative therapies to the market. For example, AL-S Pharma initiated phase 2 trials for AP-101 in 2021, expected to complete in January 2025, and Clene Nanomedicine started phase 2 trials for CNMAu8, completing in December 2024. The emphasis on new therapeutics is expected to significantly drive market growth.
Growth Factors
The global ALS therapeutics market is fueled by the growing burden of ALS and government initiatives supporting research and development. Drugs like Radicava (edaravone), approved by the U.S. FDA, slow disease progression, increasing demand. The prevalence of ALS has been rising worldwide; for instance, in Sardinia, Italy, ALS prevalence increased from 15.26 per 100,000 in 2015 to 18.31 per 100,000 in 2019. Governments are investing in research, such as Canada's USD 40 million funding via CIHR in 2023, to advance therapeutic options.
Restraining Factors
High costs and side effects associated with ALS drugs limit market growth. Treatments like Radicava can cost approximately USD 171,000 per year and may cause dizziness, weakness, and breathing issues. The high cost and adverse effects often push patients toward alternative therapies, including nutritional support, speech therapy, physical therapy, and surgery, restraining the adoption of ALS therapeutics.
Market Segmentation
By Drug Type:
- Edaravone is projected to dominate with 57.88% share in 2026, driven by global approvals and oral/parenteral availability.
- Others, including pipeline drugs like CNMAu8, MRG-001, and AP-101, also show strong growth potential.
By Route of Administration:
- Oral drugs dominated in 2026 with 50.24% share, driven by Relyvrio and other oral formulations like Radicava and Rilutek.
- The parenteral segment is expected to grow at the fastest CAGR, aided by QALSODY's approval.
By Distribution Channel:
- Hospital pharmacies led with 54.29% share in 2026, supported by trained staff and patient preference.
- Retail and online pharmacies are growing fastest, facilitated by orphan drug distribution online.
Regional Insights
North America dominated in 2025 with USD 0.48 billion, projected to reach USD 0.55 billion in 2026 due to strong drug commercialization and approvals. The U.S. market alone is forecast to reach USD 0.504 billion in 2026.
Europe contributed USD 0.24 billion in 2025, expected to grow to USD 0.27 billion in 2026, supported by QALSODY and Radicava commercialization and pipeline approvals.
Asia Pacific had USD 0.09 billion in 2025, projected to reach USD 0.12 billion in 2026, experiencing the fastest CAGR due to rising awareness and clinical trials by PTC Therapeutics and Clene Nanomedicine. Japan is expected at USD 31.6 million in 2025, China at USD 0.028 billion in 2026, and India at USD 0.009 billion in 2026.
The rest of the world is anticipated to grow substantially due to increased awareness and ALS prevalence.
Key Players
Prominent market players include Biogen, Mitsubishi Tanabe Pharma, Sanofi, EDW Pharma, Aquestive Therapeutics, Otsuka Pharmaceutical, Novartis, Zydus Lifesciences, Clene Nanomedicine, and Annexon. These companies focus on drug commercialization, clinical trials, and mergers & acquisitions to enhance their product portfolios.
Recent Developments:
- May 2024: Biogen received European approval for QALSODY.
- May 2022: Mitsubishi Tanabe Pharma gained U.S. FDA approval for Radicava.
- May 2022: Sanofi initiated Phase 2 HIMALAYA Study for SAR443820.
- March 2022: Aquestive Therapeutics licensed Riluzole oral film in China.
Conclusion
The global amyotrophic lateral sclerosis therapeutics market is projected to exhibit strong growth from USD 0.89 billion in 2025 to USD 2.19 billion by 2034 at a CAGR of 9.93%, driven by rising ALS prevalence, novel drug development, and supportive government initiatives. However, high treatment costs and side effects may restrain adoption, while oral drug formulations and hospital pharmacy distribution dominate market segments. North America remains the largest market, with Asia Pacific demonstrating the fastest growth potential.
Segmentation By Drug Type
- Tofersen
- Edaravone
- Riluzole
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacy
- Retail & Online Pharmacy
By Region
- North America (by Drug Type, by Route of Administration, by Distribution Channel, and by Country)
- U.S.
- Canada
- Europe (by Drug Type, by Route of Administration, by Distribution Channel, and by Country/Sub-region)
- U.K.
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific (by Drug Type, by Route of Administration, by Distribution Channel, and by Country/Sub-region)
- Japan
- China
- Australia
- India
- Rest of Asia Pacific
- Rest of the World (by Drug Type, by Route of Administration, and by Distribution Channel)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Epidemiology of Amyotrophic Lateral Sclerosis - by Key Countries/Regions, 2025
- 4.2. Pipeline Analysis - by Key Companies
- 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.4. Impact of COVID-19 on the Market
5. Global Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Type
- 5.1.1. Tofersen
- 5.1.2. Edaravone
- 5.1.3. Riluzole
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital Pharmacy
- 5.3.2. Retail & Online Pharmacy
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
6. North America Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Type
- 6.1.1. Tofersen
- 6.1.2. Edaravone
- 6.1.3. Riluzole
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1. Hospital Pharmacy
- 6.3.2. Retail & Online Pharmacy
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Type
- 7.1.1. Tofersen
- 7.1.2. Edaravone
- 7.1.3. Riluzole
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1. Hospital Pharmacy
- 7.3.2. Retail & Online Pharmacy
- 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Rest of Europe
8. Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Type
- 8.1.1. Tofersen
- 8.1.2. Edaravone
- 8.1.3. Riluzole
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1. Hospital Pharmacy
- 8.3.2. Retail & Online Pharmacy
- 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. Australia
- 8.4.4. India
- 8.4.5. Rest of Asia Pacific
9. Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Type
- 9.1.1. Tofersen
- 9.1.2. Edaravone
- 9.1.3. Riluzole
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1. Hospital Pharmacy
- 9.3.2. Retail & Online Pharmacy
10. Competitive Analysis
- 10.1. Global Market Share Analysis (2025)
- 10.2. Company Profiles
- 10.2.1. Biogen
- 10.2.1.1. Overview
- 10.2.1.2. Products & services
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. Mitsubishi Tanabe Pharma
- 10.2.2.1. Overview
- 10.2.2.2. Products & services
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Sanofi
- 10.2.3.1. Overview
- 10.2.3.2. Products & services
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. EDW Pharma, Inc.
- 10.2.4.1. Overview
- 10.2.4.2. Products & services
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Aquestive Therapeutics
- 10.2.5.1. Overview
- 10.2.5.2. Products & services
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Otsuka Pharmaceutical, Inc.
- 10.2.6.1. Overview
- 10.2.6.2. Products & services
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. Novartis Pharmaceuticals
- 10.2.7.1. Overview
- 10.2.7.2. Products & services
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Zydus Lifesciences Limited
- 10.2.8.1. Overview
- 10.2.8.2. Products & services
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Clene Nanomedicine
- 10.2.9.1. Overview
- 10.2.9.2. Products & services
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Strategies
- 10.2.9.6. Financials (Based on Availability)
- 10.2.10. Annexon, Inc.
- 10.2.10.1. Overview
- 10.2.10.2. Products & services
- 10.2.10.3. SWOT Analysis
- 10.2.10.4. Recent Developments
- 10.2.10.5. Strategies
- 10.2.10.6. Financials (Based on Availability)
- 10.2.1. Biogen
List of Tables
- Table 1: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
- Table 2: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 3: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 4: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 5: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
- Table 6: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 7: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 8: North America Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 9: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
- Table 10: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 11: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 12: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 13: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
- Table 14: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 15: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 16: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 17: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Drug Type, 2021-2034
- Table 18: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 19: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034a
List of Figures
- Figure 1: Global Amyotrophic Lateral Sclerosis Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2021 & 2034
- Figure 2: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2021 & 2034
- Figure 3: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2021 & 2034
- Figure 4: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2021 & 2034
- Figure 5: Global Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Region, 2021 & 2034
- Figure 6: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
- Figure 7: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
- Figure 8: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
- Figure 9: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 10: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
- Figure 11: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 12: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), By Country, 2021 & 2034
- Figure 13: North America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), By Country, 2025
- Figure 14: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
- Figure 15: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
- Figure 16: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
- Figure 17: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 18: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
- Figure 19: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 20: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), By Country/ Sub-region, 2021 & 2034
- Figure 21: Europe Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 22: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
- Figure 23: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
- Figure 24: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
- Figure 25: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 26: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
- Figure 27: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 28: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), By Country/ Sub-region, 2021 & 2034
- Figure 29: Asia Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 30: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Drug Type, 2021 & 2034
- Figure 31: Latin America Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Drug Type, 2025
- Figure 32: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Route of Administration, 2021 & 2034
- Figure 33: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 34: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value (USD billion), by Distribution Channel, 2021 & 2034
- Figure 35: Rest of the World Amyotrophic Lateral Sclerosis Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 36: Global Amyotrophic Lateral Sclerosis Therapeutics Market Share (%), By Company, 2025
